KLRK1 and neoplasm: The authors found that pretreatment of xenograft model with the modified NK cells resisted CAR T cells to the TME suppression, and improved tumor infiltration and efficacy of CAR T cells through killing NKG2D ligand-expressing tumor cells and MDSCs.